MedWatch

Finance analyst: Eli Lilly deals hard blow to Novo Nordisk with new data

While many Danish analysts were not overly concerned by Eli Lilly's novel data for tirzepatide as a rival to Novo Nordisk's semaglutide, financial analyst Jefferies sees the new data as a considerable threat against Novo Nordisk's market shares.

Photo: Darron Cummings/AP/Ritzau Scanpix

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

WS Audiology plans to list subsidiary

Privately-owned hearing aid company WS Audiology, which grew out of the merger between Widex and Sivantos, plans to list Hear.com, which handles online sales.

Further reading

Related articles

Latest news

See all jobs